Another 'Practice-Changing' Study in High-Risk Bladder Cancer

(MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118010

Author :

Publish date : 2025-10-17 20:54:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Another ‘Practice-Changing’ Study in High-Risk Bladder Cancer

Immunotherapy Gets ‘Meaningful’ Survival Win in Operable Gastric Cancer

Does the AMA Have a Seat at Trump’s Table?

Related Posts

PANDA Revisited: Sertraline’s Early Benefit Missed

Spain Breaks Health Barriers With New Guinness World Records

Is the expansion of the universe slowing down?

Final Medicare Physician Fee Schedule Rule Displeases Doc Groups

FDA’s Botox Warning Targets Websites With Unapproved Products

Study Suggests Concerning Connections Between Seizures and Heart Disease

PANDA Revisited: Sertraline’s Early Benefit Missed

Spain Breaks Health Barriers With New Guinness World Records

Is the expansion of the universe slowing down?

Final Medicare Physician Fee Schedule Rule Displeases Doc Groups

FDA’s Botox Warning Targets Websites With Unapproved Products

Study Suggests Concerning Connections Between Seizures and Heart Disease

Unusual Adverse Events After Treatment for Relapsed/Refractory Multiple Myeloma

Achieving Cure in Multiple Myeloma

Categories

Archives